← back to search

Asif Rashid

The University of Texas Health Science Center at Houston · US
Area of research
Surgery · Oncology
Research interest
Research focused on Gallstones and Inflammation, with related work in Gallbladder cancer, Transcriptome, Cancer research. Notable publications include 'Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway', 'Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma', and 'miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells'.
h-index
citations
797
works
10
NIH funding
primary concept
email

Recent publications

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America
Hepatology 2024cited by 37position: middledoi
Telomere dysfunction activates YAP1 to drive tissue inflammation
Nature Communications 2020cited by 79position: middledoi
A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer
Hepatology 2019cited by 58position: middledoi
Association of circulating inflammation proteins and gallstone disease
Journal of Gastroenterology and Hepatology 2018cited by 90position: middledoi
Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway
Gastroenterology 2017cited by 150position: middledoi
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology 2017cited by 129position: middledoi
Association of Aflatoxin and Gallbladder Cancer
Gastroenterology 2017cited by 81position: middledoi
Diet and biliary tract cancer risk in Shanghai, China
PLoS ONE 2017cited by 44position: middledoi
miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells
Cancer Research 2015cited by 97position: middledoi
Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer
International Journal of Radiation Oncology*Biology*Physics 2014cited by 32position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Bingsheng Wang · Sinopec (China)4 papers (2017–2019)Ann W. Hsing · Stanford Medicine4 papers (2017–2019)Jill Koshiol · Center for Cancer Research4 papers (2017–2019) · 2 papers (2017–2017) · 2 papers (2018–2019)Ruth M. Pfeiffer · National Institutes of Health2 papers (2018–2019)Allan Hildesheim · Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud2 papers (2017–2018)Emma E. McGee · Center for Cancer Research2 papers (2018–2019)Yu‐Tang Gao · New York University2 papers (2018–2019)Bibhuti Mishra · George Washington University1 papers (2017–2017)John A. Goss · Michael E. DeBakey VA Medical Center1 papers (2017–2017) · 1 papers (2017–2017)Ray‐Chang Wu · George Washington University1 papers (2017–2017) · 1 papers (2018–2018)Yu-Tang Gao · Fudan University1 papers (2017–2017) · 1 papers (2017–2017) · 1 papers (2015–2015)Yehuda Z. Patt · University of New Mexico1 papers (2017–2017)Pramila R. Anné · Thomas Jefferson University1 papers (2014–2014)Manal M. Hassan · WinnMed1 papers (2017–2017)